News | Ventricular Assist Devices (VAD) | March 09, 2017

Collaboration by Metro Detroit Cardiologists Increases Cardiogenic Shock Survival Rate

Heart attack patients treated with Impella heart pump early have seen an 80 percent survival rate

Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative

March 9, 2017 — Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from heart attacks.

The Detroit Cardiogenic Shock Initiative doubled survival rates in patients experiencing a life-threatening side-effect to a heart attack, the group announced recently in Detroit.

“This unprecedented effort shows the powerful advances we can make to save lives by working together in metro Detroit,” said lead investigator William W. O’Neill, M.D., director of the Center for Structural Heart Disease at Henry Ford Health System.

Watch a VIDEO interview with O'Neill at ACC.17  - "Cardiogenic Shock Supported With Impella Shows Good Outcomes."

The initiative addresses cardiogenic shock, a devastating complication of heart attacks. In these patients, the pump function of the heart is severely depressed, causing low blood pressure and vital organs to be deprived of sufficient blood supply. Despite contemporary treatments, about 50 percent of patients experiencing the condition die.

The health systems participating in the initiative have agreed to use a heart pump the size of a straw to keep blood pumping throughout the body. The Impella pump, a U.S. Food and Drug Administration (FDA)-approved device, is inserted through a catheter in the groin into the heart as soon as the patient arrives at the hospital. Doctors then treat the cause of the heart attack, either inserting a stent, removing a clot or taking other necessary action while the tiny pump supports circulation in the rest of the body.

The key difference with this initiative is that the Impella system is placed before standard treatment to fix the blocked artery.

“There is no question in our minds that early circulatory support is critical to improve the chance of a successful outcome in these critically ill patients,” said Simon Dixon, M.D., chair of cardiovascular medicine at Beaumont Hospital, Royal Oak, Mich.

Since the initiative began in July 2016, doctors at the participating hospitals found the approach was the most appropriate way to treat 30 patients who were having a heart attack and showing signs of cardiogenic shock. The treatment resulted in an 80 percent survival rate, compared to the traditional 50 percent survival rate.

“Cardiologists have been trying to move the needle on heart attack survival rate for years; this is a huge success,” said Thomas Lalonde, M.D., chief of cardiology at St. John Hospital in Detroit.

Superior Air-Ground Ambulance Service, Inc. is also supporting the initiative when transporting heart attack patients showing signs of cardiogenic shock.

O’Neill is scheduled to mention the initiative’s results in a presentation at the annual American College of Cardiology (ACC) Scientific Sessions, March 17-19 in Washington, D.C. Cardiologists in Boston, Los Angeles and other cities in the United States are following the initiative closely, to replicate for patients there, O’Neill said.

"This is a chance for a number of excellent programs from southeast Michigan to collaborate for the benefit of our patients," said Arthur Szyniszewski, M.D., cardiologist at Saint Joseph Mercy Health System.

Watch a VIDEO demonstration of how the Impella works.

Read the article “Study Examines Influence of Cardiac Arrest and Cardiogenic Shock on STEMI Patient Outcomes/“

The read article "Study Finds Impella Heart Pump Reduces Kidney Injury Risk During High-Risk PCI."

For more information: www.henryford.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init